Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma

​ Conditions: Multi Center; Phase 2; Golcadomide; Glofitamab; Polauzumab; Vedotin; G2p; B Cell Lymphoma

Interventions: Drug: golcadomide; Drug: Obinutuzumab; Drug: Polatuzumab; Drug: Glofitamab

Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb; Genentech, Inc.

Not yet recruiting Conditions: Multi Center; Phase 2; Golcadomide; Glofitamab; Polauzumab; Vedotin; G2p; B Cell Lymphoma
Interventions: Drug: golcadomide; Drug: Obinutuzumab; Drug: Polatuzumab; Drug: Glofitamab
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb; Genentech, Inc.
Not yet recruiting